Literature DB >> 10915746

Specific detection of minus-strand hepatitis C virus RNA by reverse-transcription polymerase chain reaction on PolyA(+)-purified RNA.

S T Takyar1, D s Li, Y h Wang, R Trowbridge, E J Gowans.   

Abstract

A full-length complementary DNA (cDNA) clone of the hepatitis C virus (HCV) genome was used to prepare full-length plus- and minus-strand RNA. The minus-strand RNA, which contains a polyA(+) tract complementary to the polyU tract found in the plus strand (genomic) RNA, but not the plus strand RNA, was captured with a commercial polyA(+)-tract isolation system. After elution, the minus strand was amplified by reverse-transcription polymerase chain reaction (RT-PCR). The combination of this procedure and RT-PCR using rTth resulted in an unprecedented level of discrimination of 10 logs(10). HCV minus-strand RNA isolation was unaffected by the addition of an excess of 10(4) of plus strands or by the addition of cellular RNA, and although the polyA(+) isolation step removed 99. 99% of plus strands, there was no loss of minus-strand signal. Minus-strand RNA was detected in RNA extracted from 4/4 liver samples and 4/8 peripheral blood mononuclear cells (PBMC) samples examined. Because the titer of plus-strand HCV RNA in any sample makes a significant contribution to false, random, and self-priming, removal of the plus strand in this manner results in the most accurate method yet devised to confirm the replication of HCV in a population of cells.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10915746     DOI: 10.1053/jhep.2000.9094

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  13 in total

1.  Expression of microRNA miR-122 facilitates an efficient replication in nonhepatic cells upon infection with hepatitis C virus.

Authors:  Takasuke Fukuhara; Hiroto Kambara; Mai Shiokawa; Chikako Ono; Hiroshi Katoh; Eiji Morita; Daisuke Okuzaki; Yoshihiko Maehara; Kazuhiko Koike; Yoshiharu Matsuura
Journal:  J Virol       Date:  2012-05-16       Impact factor: 5.103

2.  Hepatitis C virus productive infection in mononuclear cells from patients with cryoglobulinaemia.

Authors:  D Sansonno; F A Tucci; G Lauletta; V De Re; M Montrone; L Troiani; L Sansonno; F Dammacco
Journal:  Clin Exp Immunol       Date:  2007-02       Impact factor: 4.330

3.  Hepatitis C virus infection of human hepatoma cell line 7721 in vitro.

Authors:  Z Q Song; F Hao; F Min; Q Y Ma; G D Liu
Journal:  World J Gastroenterol       Date:  2001-10       Impact factor: 5.742

4.  Does occult hepatitis C virus infection exist?

Authors:  Vicente Carreño; Javier Bartolomé; Inmaculada Castillo; Juan Antonio Quiroga
Journal:  J Clin Microbiol       Date:  2008-10       Impact factor: 5.948

5.  Vitamin B12 and hepatitis C: molecular biology and human pathology.

Authors:  W B Lott; S S Takyar; J Tuppen; D H Crawford; M Harrison; T P Sloots; E J Gowans
Journal:  Proc Natl Acad Sci U S A       Date:  2001-04-10       Impact factor: 11.205

Review 6.  Central nervous system involvement in hepatitis C virus infection.

Authors:  Daniel M Forton; Howard C Thomas; Simon D Taylor-Robinson
Journal:  Metab Brain Dis       Date:  2004-12       Impact factor: 3.584

Review 7.  Hepatitis C virus-induced cryoglobulinemia.

Authors:  Edgar D Charles; Lynn B Dustin
Journal:  Kidney Int       Date:  2009-07-15       Impact factor: 10.612

8.  Identification of unique hepatitis C virus quasispecies in the central nervous system and comparative analysis of internal translational efficiency of brain, liver, and serum variants.

Authors:  Daniel M Forton; Peter Karayiannis; Nadiya Mahmud; Simon D Taylor-Robinson; Howard C Thomas
Journal:  J Virol       Date:  2004-05       Impact factor: 5.103

9.  In vitro systems for the study of hepatitis C virus infection.

Authors:  Garrick K Wilson; Zania Stamataki
Journal:  Int J Hepatol       Date:  2012-09-27

Review 10.  Human cell types important for hepatitis C virus replication in vivo and in vitro: old assertions and current evidence.

Authors:  Dennis Revie; Syed Zaki Salahuddin
Journal:  Virol J       Date:  2011-07-11       Impact factor: 4.099

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.